Dr. Stephen McCormack is a medical entrepreneur with over 25 years of experience in the medical device and health and wellness industry, from fundamental research and technology development to intellectual property and commercialization of implantable medical devices. His expertise in formation, capitalization and management of businesses in healthcare has resulted in the creation of significant economic value to investors and medical value to society. He has experience in roll-ups of healthcare services business in the hearing aid industry as well as optometric and ophthalmological practices. In addition, he is well versed in M&A strategies of healthcare businesses to realize synergies and enhance shareholder value.
Dr. McCormack has co-founded and operated several successful ventures in the healthcare industry during his near three decade long career. He was the Chief Executive Officer of Intelligent Medical Implants (IMI) in Bonn, Germany. IMI is now a publically traded company on the EuroNext exchange under the name Pixium Vision (PIX.PA) which is developing an implantable retinal prosthetic device to restore functional vision to the blind. Prior to that, he was a Managing Director at Global Life Science Ventures in Zug, Switzerland. His other previous companies include AlleCure, MannKind (NASDAQ: MNKD), AOS/EHS, NeuroSystec, CytoMx/Cynvenio and most recently Visus Technology. He has been an active investor and contributing board member of over a dozen companies in the industry. He is currently a board member of the Treatment Research Institute and an advisor to The Albany College of Pharmacy.
Dr. McCormack received his PhD in the Interdepartmental Biomolecular Science and Engineering program from University of California, Santa Barbara. He obtained a bachelor’s degree in biology from the College of the Holy Cross in Worcester, MA.